The treatment of advanced bladder cancer with methotrexate and cis-platinum—a pharmacokinetic study

Kaye, Stanley B.; McWhinnie, D. L.; Hart, A. J. L.; Deane, R. F.; Billaert, P.; Welsh, John; Milsted, R.; Stuart, J. F. B.; Calman, Kenneth C.

doi:10.1016/0277-5379(84)90191-3

Cited by 16 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MTX has been used for bladder cancer treatment since the 1970s to the 1980s of the last century [10,[156][157][158][159][160][161][162][163]227,228,272]. It was used both alone [10,156,158,228] and in combination regimens with such antineoplastic agents as PDD, vinblastine, Adriamycin, 5-FU, vincristine, bleomycin, mitomycin C or cyclophosphamide [10,[159][160][161][162]272]. MTX used as a single agent is one of the most active drugs [161].…”

Section: Methotrexate-based Therapy Of Prostate and Bladder Cancersmentioning

confidence: 99%

“…The authors concluded that transurethral resection followed by HDMTX application may offer an effective alternative to radiotherapy or cystectomy for many patients with invasive bladder cancer. Kaye et al described the results of the patients with advanced bladder cancer using MTX alone or in combination with PDD [159]. The obtained results showed that patients with satisfactory renal function can receive low doses of both drugs simultaneously without risk of enhanced toxicity.…”

Section: Methotrexate-based Therapy Of Prostate and Bladder Cancersmentioning

confidence: 99%

See 1 more Smart Citation

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers

Koźmiński

Halik

Chesori

et al. 2020

IJMS

207

120

View full text Add to dashboard Cite

Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases. In this paper, we take an overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy. In addition, the issue of the potential benefits of methotrexate in the development of neurological disorders in Alzheimer’s disease or myasthenia gravis will be discussed.

show abstract

Section: Methotrexate-based Therapy Of Prostate and Bladder Cancersmentioning

confidence: 99%

Section: Methotrexate-based Therapy Of Prostate and Bladder Cancersmentioning

confidence: 99%

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers

Koźmiński

Halik

Chesori

et al. 2020

IJMS

207

120

View full text Add to dashboard Cite

show abstract

“…No effects have been reported of hyperhydration on topotecan and (medium dose) methotrexate PK. 18,19 There are a few limitations to our study. The first is that the effect of cisplatin or hyperhydration cannot be distinguished.…”

Section: Discussionmentioning

confidence: 98%

“…For other renally excreted drugs coadministered with cisplatin and hyperhydration, some small PK studies have been performed. No effects have been reported of hyperhydration on topotecan and (medium dose) methotrexate PK 18,19 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperhydration with cisplatin does not influence pemetrexed exposure

Rouw

Derijks

Hilbrands

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Pemetrexed is a cytotoxic drug for first-line treatment of lung cancer. It is often combined with other anticancer drugs such as cisplatin or carboplatin. In clinical practice, hyperhydration regimens are applied to overcome cisplatin-related nephrotoxicity. As pemetrexed is almost completely eliminated from the body by the kidneys, hyperhydration can result in augmented clearance. Furthermore, administration of large quantities of fluid may increase the volume of distribution of pemetrexed. Pharmacokinetics and, thus, efficacy and toxicity may be influenced by hyperhydration. This has not yet been properly studied. We performed a population pharmacokinetic analysis to assess hyperhydration as a covariate for pemetrexed clearance and for volume of distribution A relevant change was defined as >25% increase in clearance or volume of distribution. In our extensive dataset of 133 individuals, we found that hyperhydration did not significantly or relevantly explain variability in pemetrexed clearance (unchanged, P = .196) or volume of distribution (+7% change, P = .002), despite a power of >99% to detect a relevant change. Therefore, dose adjustments of pemetrexed are not required during hyperhydration with cisplatin.

show abstract

Systemic chemotherapy of transitional cell carcinoma of the urothelium

Brinkley

Torti

1997

Semin. Surg. Oncol.

View full text Add to dashboard Cite

Although the incidence of bladder cancer has increased in recent years, survival has also improved. Chemotherapy has made a substantial impact on this disease and now is used in patients with advanced or metastatic disease as well as in select patients with high‐risk muscle invasive disease. While cisplatin remains the most active single antineoplastic agent, several other agents including methotrexate, vinblastine, and Adriamycin (doxorubicin) have important activity. More recently, paclitaxel and gemcitabine have shown promising activity in bladder cancer. Multidrug combination therapy has provided more frequent and durable responses than single agent therapy. Regimens containing cisplatin and methotrexate have been shown to be most effective in the treatment of advanced disease. Adjuvant chemotherapy regimes typically have included cisplatin or cisplatin and methotrexate combinations. However, studies have been limited and further prospective trials are required to determine the role of adjuvant chemotherapy. Multiple studies have investigated neoadjuvant chemotherapy with cisplatin and methotrexate combinations or anthracycline‐based regimens, but study results are mixed. Further trials will be required to define the role of neoadjuvant chemotherapy in bladder cancer. Semin. Surg. Oncol. 13:365‐375, 1997. © 1997 Wiley‐ Liss, Inc.

show abstract

The treatment of advanced bladder cancer with methotrexate and cis-platinum—a pharmacokinetic study

Cited by 16 publications

References 2 publications

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers

Hyperhydration with cisplatin does not influence pemetrexed exposure

Systemic chemotherapy of transitional cell carcinoma of the urothelium

Contact Info

Product

Resources

About